Tegoprubart

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

Therapeutic Areas